Capital Impact Advisors, LLC Allogene Therapeutics, Inc. Transaction History

Capital Impact Advisors, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 23, 2023	BUY	$4.92 - $8.21 $45,141 - $75,326	9,175 Added 54.29%	26,076 $128,000
Q4 2022 Feb 14, 2023	SELL	$5.62 - $11.11 $14,825 - $29,308	-2,638 Reduced 13.5%	16,901 $106,000
Q3 2022 Nov 21, 2022	BUY	$10.32 - $17.28 $39,618 - $66,337	3,839 Added 24.45%	19,539 $196,000
Q2 2022 Aug 15, 2022	BUY	$6.78 - $12.28 $106,446 - $192,796	15,700 New	15,700 $179,000
Q1 2021 May 18, 2021	SELL	$25.79 - $39.02 $1.08 Million - $1.63 Million	-41,800 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$25.24 - $43.45 $2.16 Million - $3.71 Million	-85,396 Reduced 67.14%	41,800 $1.06 Million
Q3 2020 Nov 13, 2020	BUY	$32.38 - $44.96 $2.91 Million - $4.05 Million	90,000 Added 241.96%	127,196 $4.8 Million
Q2 2020 Aug 17, 2020	SELL	$18.39 - $54.04 $760,169 - $2.23 Million	-41,336 Reduced 52.64%	37,196 $1.59 Million
Q1 2020 May 15, 2020	BUY	$18.22 - $28.25 $56,737 - $87,970	3,114 Added 4.13%	78,532 $1.53 Million
Q3 2019 Nov 14, 2019	BUY	$26.11 - $32.99 $280,839 - $354,840	10,756 Added 16.63%	75,418 $2.06 Million
Q2 2019 Jul 19, 2019	BUY	$25.56 - $31.09 $1.65 Million - $2.01 Million	64,662 New	64,662 $1.72 Million

163

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $240M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Capital Impact Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Capital Impact Advisors, LLC with notifications on news.